[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia]

S I Moiseev; K M Abdulkadyrov; L N Bubnova; T V Glazanova; O E Rozanova; I E Pavlova; V A Balashova; A L Kovalenko

[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia]

Vopr Onkol. 1999;45(4):405-10.

[Article in Russian]

Authors

S I Moiseev¹, K M Abdulkadyrov, L N Bubnova, T V Glazanova, O E Rozanova, I E Pavlova, V A Balashova, A L Kovalenko

Affiliation

¹ Russian Research Institute of Hematology and Transfusiology, St. Petersburg.

PMID: 10532100

Abstract

The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.

Publication types

Clinical Trial

MeSH terms

Acridines / therapeutic use*
Adjuvants, Immunologic / therapeutic use*
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Combined Modality Therapy
Female
Humans
Interferon Inducers / therapeutic use*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / immunology
Male
Middle Aged
Treatment Outcome

Substances

Acridines
Adjuvants, Immunologic
Interferon Inducers
10-carboxymethyl-9-acridanone